02616 CSTONE PHARMA-BWatchlist
About CSTONE PHARMA-B Company
Cornerstone Pharmaceutical was created to meet the needs of cancer patients and focuses on developing and commercializing innovative tumor immunotherapy and molecular-targeted drugs. Since its establishment 3 years ago, the company has assembled a world-class management team with rich experience in preclinical research, clinical development and commercialization. Through a dual source of innovation consisting of internal R&D and external collaboration, the company has built a powerful anti-tumor drug pipeline with 14 drug candidates, including 4 products exclusively collaborated and authorized by Blueprint Medicine and Agios Pharmaceuticals. Together with the self-developed pipeline, the company has significant potential and synergistic effects for single and combination therapies. Of the drug candidates under development, 4 are in or close to critical trials. Cornerstone Pharmaceutical's business model is driven by clinical research and development, while rapidly establishing commercialization and production capacity. The company received support from well-known investors, and both the A and B rounds of financing broke records in the biomedical field at the time, with a total amount of 412 million US dollars in the two rounds of financing. With an experienced team, a promising R&D pipeline, a strong business model, and sustainable financial support, Cornerstone's vision is to become a world-renowned leading Chinese biopharmaceutical company by bringing innovative and differentiated oncology therapies to cancer patients around the world.
Insider Buyers At CStone Pharmaceuticals Likely Disappointed With 16% Slide
Insiders who bought CN¥6.54m worth of CStone Pharmaceuticals' (HKG:2616) stock at an average buy price of CN¥2.52 over the last year may be disappointed by the recent 16% decrease in the stock. This
Hong Kong Stock Announces Nuggets | Strategic Cooperation with Foreign Countries: World's First and Only R/R ENKTL Immunotherapy Drug Approved to Open Overseas Markets
Puget is a potent, highly selective inhibitor that accurately targets RET targets.
Cornerstone Pharmaceutical-B (02616.HK): Grants 14 million share options under the post-IPO employee stock ownership plan
On November 9, Gelonghui - Cornerstone Pharmaceutical-B (02616.HK) issued an announcement. On November 8, 2023, the company granted Dr. Yang Jianxin a total of 14 million share options to subscribe for a total of 14 million shares in accordance with the initial public offering after-sales employee stock ownership plan.
Clinical approvals continue to be obtained. That's not good for the market. It becomes a bad day. That means the company will continue to burn cash. After entering shenzhen-Hong Kong stock connect, trading volume is even more depressed. Cornerstones become stepping stones. There was no agency to recommend it. Share prices have given up all this year's gains. This is cstone's darkest hour.